Santhera Pharmaceuticals Holding AG

SANN

CH1276028821

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:30:02 2024-05-17 am EDT			5-day change	1st Jan Change
9.25 ^CHF	-0.96%		+0.87%	-5.71%

Apr. 25	Transcript : Santhera Pharmaceuticals Holding AG, 2023 Earnings Call, Apr 25, 2024
Apr. 25	Santhera Pharmaceuticals Swings to Profit in FY23; Revenue Grows	MT

Santhera Pharmaceuticals Holding AG Announces Nomination of Directors

February 31, 2017

Santhera Pharmaceuticals Holding AG announced that its Board of Directors is nominating Elmar Schnee, Philipp Gutzwiller, Patrick Vink, MD, and Thomas Meier, PhD and CEO of Santhera, for election to the Board of Directors at the Annual Shareholders' Meeting to be held on April 4, 2017. Thomas Meier will also be proposed as Delegate of the Board.

Latest news about Santhera Pharmaceuticals Holding AG

Transcript : Santhera Pharmaceuticals Holding AG, 2023 Earnings Call, Apr 25, 2024	Apr. 25
Santhera Pharmaceuticals Swings to Profit in FY23; Revenue Grows	Apr. 25	MT
Santhera Pharmaceuticals Holding AG Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 25	CI
Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis	Apr. 17	MT
Santhera Pharmaceuticals Wins Priority Review for Duchenne Muscular Dystrophy Drug in China	Mar. 27	MT
Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Grants Priority Review by China's NMPA	Mar. 27	CI
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical?s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology	Feb. 21	CI
Santhera's New Study Shows Efficacy, Safety Data for Duchenne Muscular Dystrophy Treatment	Feb. 14	MT
Santhera Pharmaceuticals Holding AG Launches AGAMREE in Germany as First Market for the Treatment of Duchenne Muscular Dystrophy	Jan. 15	CI
Swiss Equities Get a Boost from UK’s Upside GDP Surprise	Jan. 12	MT
Santhera Pharmaceuticals Obtains UK Approval for Duchenne Muscular Dystrophy Treatment	Jan. 12	MT
Swiss Equities Edge Down After Central Banks Buzz	Dec. 18	MT
Santhera Pharmaceuticals Wins EU Nod for Duchenne Muscular Dystrophy Drug	Dec. 18	MT
Santhera Pharmaceuticals Names Chief Commercial, Technology Officers	Dec. 07	MT
Santhera Pharmaceuticals Holding Ag Promotes Promotion of Geert Jan Van Daal to Chief Commercial Officer and of Marc Schrader to Chief Technology Officer	Dec. 07	CI
Santhera Pharmaceuticals Receives U.S. FDA Approval of Agamree(R) for the Treatment of Duchenne Muscular Dystrophy	23-10-27	CI
Santhera, Catalyst Pharmaceuticals Secure US FDA Nod for Rare Neuromuscular Disease Drug	23-10-26	MT
Catalyst Pharmaceuticals Says Santhera's Agamree Gains FDA Approval for Duchenne Muscular Dystrophy Treatment	23-10-26	MT
Catalyst Pharmaceuticals to Commercialize Duchenne Treatment in 1Q24 After FDA Approval	23-10-26	DJ
US FDA approves Santhera's drug for rare muscular dystrophy	23-10-26	RE
US FDA approves Santhera's Duschenne drug	23-10-26	RE
Santhera Gets Positive Opinion From European Medicines Agency's Committee for Duchenne MD Drug	23-10-13	MT
Santhera Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of AGAMREE®? for the Treatment of Duchenne Muscular Dystrophy	23-10-13	CI
Transcript : Santhera Pharmaceuticals Holding AG, H1 2023 Earnings Call, Sep 07, 2023	23-09-07
Santhera Pharmaceuticals Narrows H1 Attributable Loss; Revenue Down	23-09-07	MT

Chart Santhera Pharmaceuticals Holding AG

Duration

Period

Chart Santhera Pharmaceuticals Holding AG

More charts

Company Profile

Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company operates through one business segment, which is the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases, such as Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF). The Company focuses also on development of gene therapy for the treatment of LAMA2 (Laminin Subunit Alpha 2) deficient congenital muscular dystrophy (CMD). Santhera operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.

Sector

Pharmaceuticals

Calendar

2024-05-28 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

9.25 CHF

Average target price

30 CHF

Spread / Average Target

+224.32%

Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
SANTHERA PHARMACEUTICALS HOLDING AG	-5.71%	115M
KYOWA KIRIN CO. LTD.	+10.23%	8.96B
SK BIOPHARMACEUTICALS CO., LTD.	-10.76%	5.19B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+51.58%	4.77B
YUHAN CORPORATION	+12.50%	4.26B
BETTA PHARMACEUTICALS CO., LTD.	-20.70%	2.37B
INDIVIOR PLC	+12.83%	2.3B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+19.51%	2.17B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-29.65%	2.21B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B

Specialty & Advanced Pharmaceuticals